Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks-Reference-Cited by-同舟云学术

Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks

Published:2024-01 Issue:1 Volume:8 Page:102306
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Kiialainen Anna,Adamkewicz Joanne I.,Petry Claire,Oldenburg Johannes,Pipe Steven W.,Young Guy,Mahlangu Johnny,Lehle Michaela,Niggli Markus,Castaman Giancarlo,Jiménez-Yuste Víctor,Shima Midori,Négrier Claude,Schmitt Christophe

Funder

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Hematology

Reference38 articles.

1. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A;Batorova;J Med Life,2022

2. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model;Kitazawa;Nat Med,2012

3. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A;Shima;N Engl J Med,2016

4. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects;Uchida;Blood,2016

5. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A;Yoneyama;Clin Pharmacokinet,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review;Seminars in Thrombosis and Hemostasis;2024-06-27

2. Emicizumab prophylaxis in infants: Single‐centre experience;British Journal of Haematology;2024-01-24

3. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial;Blood Journal;2023-12-21